Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18227479.
- Also identified by DOI 10.2337/dc08-s243.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Decreases in both mass and secretory function of insulin-producing beta-cells contribute to the pathophysiology of type 2 diabetes. The histology of islets from patients with type 2 diabetes displays an inflammatory process characterized by the presence of cytokines, apoptotic cells, immune cell infiltration, amyloid deposits, and eventually fibrosis. This inflammatory process is probably the combined consequence of dyslipidemia, hyperglycemia, and increased circulating adipokines. Therefore, modulation of intra-islet inflammatory mediators, in particular interleukin-1 beta, appears as a promising therapeutic approach.
Medical subject headings
- Diabetes Mellitus, Type 2
- Inflammation
- Pancreatic Diseases